Effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease stages 3-5
a retrospective cohort study
Palavras-chave:
Mortality, Renal replacement therapy, Uric acidResumo
BACKGROUND: Findings regarding the effects of hyperuricemia on renal function and mortality have been inconsistent. OBJECTIVES: To investigate the effects of hyperuricemia on incident renal replacement therapy and all-cause mortality among patients with chronic kidney disease (CKD). DESIGN AND SETTING: Retrospective cohort study conducted in a medical center in Taiwan. METHODS: Patients with CKD in stages 3-5, without histories of renal replacement therapy, were consec-utively recruited from 2007 to 2013. Their medical history, laboratory and medication data were collected from hospital records. The mean uric acid level in the first year of follow-up was used for analyses. Hyper-uricemia was defined as mean uric acid level ≥ 7.0 mg/dl in men or ≥ 6.0 mg/dl in women. The primary outcomes were incident renal replacement therapy and all-cause mortality, and these data were retro-spectively collected from hospital records until the end of 2015. RESULTS: A total of 4,381 patients were analyzed (mean age 71.0 ± 14.8 years; males 62.7%), and the me-dian follow-up period was 2.5 years. Patients with hyperuricemia were at increased risk of incident renal replacement therapy and all-cause mortality, especially those with CKD in stages 4 or 5. Compared with patients with CKD in stage 3 and normouricemia, patients with CKD in stages 4 or 5 presented significantly higher risk of all-cause mortality only if they had hyperuricemia. CONCLUSIONS: In patients with CKD in stages 3-5, hyperuricemia was associated with higher risk of inci-dent renal replacement therapy and all-cause mortality. Whether treatment with uric acid-lowering drugs in these patients would improve their outcomes merits further investigation.
Downloads
Referências
Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-21. PMID: 18946066; doi: 10.1056/NEJMra0800885.
Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275(9):457-64. PMID: 5917940; doi: 10.1056/NEJM196609012750902.
Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007;115(19):2526-32. PMID: 17470699; doi: 10.1161/ CIRCULATIONAHA.106.657627.
Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001;87(12):1411-4. PMID: 11397367; doi: 10.1016/s0002-9149(01)01566-1.
Lehto S, Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29(3):635-9. PMID: 9506605; doi: 10.1161/01.str.29.3.635.
Quiñones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1):E1-5. PMID: 7840165; doi: 10.1152/ajpendo.1995.268.1.E1.
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93(6):817-21. PMID: 7447188; doi: 10.7326/0003-4819-93-6-817.
Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259. PMID: 25437867; doi: 10.1371/ journal.pone.0114259.
White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-36. PMID: 26781229; doi: 10.1016/ S2213-8587(15)00386-1.
Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407-13. PMID: 18799720; doi: 10.1681/ASN.2008010080.
Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204-11. PMID: 18337481; doi: 10.1681/ASN.2007101075.
Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta- analysis of 15 cohort studies. PLoS One. 2014;9(6):e100801. PMID: 24959886; doi: 10.1371/journal.pone.0100801.
Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27(5):435-40. PMID: 17622758; doi: 10.1159/000105142.
Nacak H, van Diepen M, Qureshi AR, et al. Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrol Dial Transplant. 2015;30(12):2039-45. PMID: 26185050; doi: 10.1093/ndt/gfv225.
Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796-803. PMID: 19303683; doi: 10.1053/j.ajkd.2008.12.021.
Weiner DE, Tighiouart H, Elsayed EF, et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis. 2008;51(2):212-23. PMID: 18215699; doi: 10.1053/j.ajkd.2007.10.035.
Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70. PMID: 10075613; doi: 10.7326/0003-4819-130-6-199903160-00002.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26. PMID: 23992601; doi: 10.1056/NEJMoa1307684.
Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301-8. PMID: 22282466; doi: 10.1158/1078-0432.CCR-11-2097.
Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642-50. PMID: 15384015.
Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264-72. PMID: 20385436; doi: 10.1053/j.ajkd.2010.01.019.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305. PMID: 15385656; doi: 10.1056/NEJMoa041031.
Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81. PMID: 20483451; doi: 10.1016/S0140-6736(10)60674-5.
Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371(9631):2173-82. PMID: 18586172; doi: 10.1016/S0140-6736(08)60952-6.
Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol. 2008;125(2):232-9. PMID: 18237790; doi: 10.1016/j.ijcard.2007.11.094.
Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231(1):61-8. PMID: 24125412; doi: 10.1016/j.atherosclerosis.2013.08.023.
Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015;22(4):513-8. PMID: 24431384; doi: 10.1177/2047487313519346.
Odden MC, Amadu AR, Smit E, Lo L, Peralta CA. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis. 2014;64(4):550-7. PMID: 24906981; doi: 10.1053/j.ajkd.2014.04.024.
Zoppini G, Targher G, Negri C, et al. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care. 2009;32(9):1716-20. PMID: 19542211; doi: 10.2337/dc09-0625.
Ong G, Davis WA, Davis TM. Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2010;53(7):1288-94. PMID: 20349345; doi: 10.1007/s00125-010-1735-7.
Xia X, Luo Q, Li B, et al. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2016;65(9):1326-41. PMID: 27506740; doi: 10.1016/j.metabol.2016.05.009.
Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis. 2018;71(3):362-70. PMID: 29132945; doi: 10.1053/j.ajkd.2017.08.017.
Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-Specific Deaths in Non-Dialysis-Dependent CKD. J Am Soc Nephrol. 2015;26:2512-20. PMID: 26045089; doi: 10.1681/ASN.2014101034.
Mok Y, Matsushita K, Sang Y, et al. Association of Kidney Disease Measures with Cause-Specific Mortality: The Korean Heart Study. PLoS One. 2016;11(4):e0153429. PMID: 27092943; doi: 10.1371/journal.pone.0153429.
Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858-62. PMID: 6947260; doi: 10.1073/pnas.78.11.6858.
Kobylecki CJ, Afzal S, Nordestgaard BG. Plasma Urate, Cancer Incidence, and All-Cause Mortality: A Mendelian Randomization Study. Clin Chem. 2017;63(6):1151-60. PMID: 28428355; doi: 10.1373/clinchem.2016.268185.
Tong L, Chuang CC, Wu S, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Lett. 2015;367(1):18-25. PMID: 26187782; doi: 10.1016/j.canlet.2015.07.008.
Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1(1):16. PMID: 23369448; doi: 10.1186/2001-1326-1-16.
Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388-93. PMID: 20538833; doi: 10.2215/ CJN.01580210.
Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis. 2015;65(4):543-9. PMID: 25595565; doi: 10.1053/j.ajkd.2014.11.016.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
